Skip to main content

IL-17

unhappy%20patient.jpg
It seems like every conference we are presented with data on the newest biologic for treatment of psoriatic arthritis, but the question is, do we need it? Oral presentation (6937) discussed that…
RT @MeralElRamahiMD: ➡️Netakimab = IL17Ai approved for AS, PsA, & Pso in Russia & Belarus

Meral K. El Ramahi, MD MeralElRamahiMD

3 months 2 weeks ago
➡️Netakimab = IL17Ai approved for AS, PsA, & Pso in Russia & Belarus
RT @MeralElRamahiMD: ⭐️JUNIPERA: RCT of SEC in active ERA & JPsA (2-18yo, most on MTX)
-Tx . (TP)1: SEC 75/100 m

Meral K. El Ramahi, MD MeralElRamahiMD

3 months 2 weeks ago
⭐️JUNIPERA: RCT of SEC in active ERA & JPsA (2-18yo, most on MTX) -Tx . (TP)1: SEC 75/100 mg till wk 12 -TP2: cont SEC or switch to PBO till wk 104 ⭐️SEC efficacious on JIA ACR30/70 ⭐️74% w/ resolution of enthes ⭐️Median T2flare in PBO in TP2 = 453d LB0004 #EULAR2021 @Rheumnow https://t.co/JsG2pXz9r6
EULAR 2021 - Day 2 Podcasts

Check out this compilation of our EULAR 2021 Day 2 broadcasts below.

You can also follow t

Dr. John Cush RheumNow

3 months 3 weeks ago
EULAR 2021 - Day 2 Podcasts Check out this compilation of our EULAR 2021 Day 2 broadcasts below. You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud. https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu
RT @ejdein1: #EULAR2021 LB0004: Secukinumab for enthesitis-related JIA treatment-withdrawal study shows longer time to f

Eric Dein ejdein1

3 months 3 weeks ago
#EULAR2021 LB0004: Secukinumab for enthesitis-related JIA treatment-withdrawal study shows longer time to flare and decreased flares compared to PBO @Rheumnow https://t.co/LG3dDmH7we
RT @doctorRBC: JUNIPERA - secukinumab in enthesitis related arthritis and juvenile PsA
⭐️achieved JIA ACR response c

Robert B Chao, MD doctorRBC

3 months 3 weeks ago
JUNIPERA - secukinumab in enthesitis related arthritis and juvenile PsA ⭐️achieved JIA ACR response compared to placebo ⭐️⬇️time to flare ⭐️75% with resolution of enthesitis ⭐️0 deaths, AE - minor infections, GI issues, headache Abs#LB0004 #EULAR2021 @RheumNow
RT @uptoTate: SPIRIT-P1&P2 studies showed IXE effective in treating axPsA. When do you consider IL17i in your treatm

Dr. Rachel Tate uptoTate

3 months 3 weeks ago
SPIRIT-P1&P2 studies showed IXE effective in treating axPsA. When do you consider IL17i in your treatment algorithm in axPsA (as the predominant domain?) Poster #POS1045 #EULAR2021 @RheumNow
×